Company Recalls Aminohippurate Sodium Injection
August 17, 1999
West Point, PA (SafetyAlerts) - The Food and Drug
Administration (FDA) today reported that Merck and Company is recalling Aminohippurate
Sodium Injection because of glass particulate contamination.
Aminohippurate Sodium Injection, 2g in 10 mL (20%
Solution) in 10 mL single dose vials, Rx used for the treatment of effective renal plasma
flow,(ERPF). NDC #0006-339511.
Lot numbers: 0703B EXP May 00, 1498B EXP May 00, 0334D EXP Nov 00, 0839D EXP Nov
00, 0178J EXP Nov 00,1075D EXP Jan 01, 1289D EXP Jan 01, 0035E EXP Jun 01,0035ESA1 EXP Jun
01, 0956E EXP May 02, 1546E EXP May 02,0476H EXP Mar 03, 1111H EXP Mar 03, 1722H EXP Jun
Merck and Company, West Point, Pennsylvania.
Manufacturer, by letter on June 9, 1999. Firm-initiated recall complete.
Nationwide and international.
Firm estimated that 300 units remained at the wholesale level at time of recall